Michaela Feuring‐Buske

Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced-stage Hodgkin’s lymphoma: results from the randomized international GHSG HD18 trial

Justin Ferdinandus, Horst Müller, Carla Damaschin, Anne Sophie Jacob et autres

BACKGROUND: Persisting cancer-related fatigue impairs health-related quality of life (HRQoL) and social reintegration in patients with Hodgkin's lymphoma (HL). The GHSG HD18 trial established treatment de-escalation for advanced-stage HL guided by positron emission tomography after two cycles (PET-2) as new standard. Here, …

de, us, ch, nl, at, cz (code pays fourni par la source)

Impact of PET‐2 guided treatment de‐escalation on time‐to‐recovery from cancer‐related fatigue in advanced stage Hodgkin Lymphoma: results from the GHSG HD18 study

Justin Ferdinandus, Horst Müller, Carla Damaschin, A. S. Jacob et autres

Introduction: Persisting cancer related fatigue (CRF) has impact on health related quality of life (HRQoL) and social re-integration of patients with Hodgkin lymphoma (HL). The GHSG HD18 trial established treatment PET-2 guided de-escalation of treatment for advanced-stage HL as new standard. Here, …

de, ch, nl, at, cz (code pays fourni par la source)

2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

Michael Heuser, Sylvie Freeman, Gert J. Ossenkoppele, Francesco Buccisano et autres

Measurable residual disease (MRD) is an important biomarker in acute myeloid leukemia (AML) that is used for prognostic, predictive, monitoring, and efficacy-response assessments. The European LeukemiaNet (ELN) MRD Working Party evaluated standardization and harmonization of MRD in an ongoing manner and has …

de, gb, nl, it, us, fr, pl, be, il (code pays fourni par la source)

PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial

Stefanie Kreissl, Helen Goergen, Ina Buehnen, Carsten Kobe et autres

de, ch, at, nl, cz (code pays fourni par la source)

Higher Dose of CPX-351 Is Associated with Prolonged Hematologic Recovery: Results from an Interim Safety Analysis of the Randomized, Phase III AMLSG 30-18 Trial

Verena I. Gaidzik, Verena Mayr-Benedikter, Daniela Weber, Anika Schrade et autres

Background: CPX-351, a liposomal formulation of daunorubicin and cytarabine in the fixed molar ratio (1:5), is approved for the treatment of adult patients (pts) with newly diagnosed acute myeloid leukemia (AML) with myelodysplasia-related changes and therapy-related AML (t-AML). To explore the potential …

de, us (code pays fourni par la source)

TET1 promotes growth of T-cell acute lymphoblastic leukemia and can be antagonized via PARP inhibition

Shiva Bamezai, Deniz Demir, Alex Jose Pulikkottil, Fabio Ciccarone et autres

de, it (code pays fourni par la source)

Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi‐centre setting

Diana Hanekamp, Alexander N. Snel, Angèle Kelder, Willemijn J. Scholten et autres

Summary Leukaemic stem cells (LSC) have been experimentally defined as the leukaemia‐propagating population and are thought to be the cellular reservoir of relapse in acute myeloid leukaemia (AML). Therefore, LSC measurements are warranted to facilitate accurate risk stratification. Previously, we published the …

nl, hr, gb, it, us, de (code pays fourni par la source)

Somatostatin receptor mediated targeting of acute myeloid leukemia by photodynamic metal complexes for light induced apoptosis

Vegi M. Naidu, Sabyasachi Chakrabortty, Maksymilian Marek Zegota, Seah Ling Kuan et autres

Abstract Acute myeloid leukemia (AML) is characterized by relapse and treatment resistance in a major fraction of patients, underlining the need of innovative AML targeting therapies. Here we analysed the therapeutic potential of an innovative biohybrid consisting of the tumor-associated peptide somatostatin …

de, in (code pays fourni par la source)

The ParaHox gene Cdx4 induces acute erythroid leukemia in mice

Silvia Thoene, Tamoghna Mandal, Vegi M. Naidu, Leticia Quintanilla‐Martínez et autres

Acute erythroid leukemia (AEL) is a rare and aggressive form of acute leukemia, the biology of which remains poorly understood. Here we demonstrate that the ParaHox gene CDX4 is expressed in patients with acute erythroid leukemia, and that aberrant expression of Cdx4 …

de (code pays fourni par la source)

Differences in expression and function of LEF1 isoforms in normal versus leukemic hematopoiesis

Kristin Feder, Katrin Elisabeth Edmaier-Schröger, Vijay P.S. Rawat, Nicole Kirsten et autres

de (code pays fourni par la source)

The microRNA miR-196b acts as a tumor suppressor in Cdx2-driven acute myeloid leukemia

Vijay P.S. Rawat, Maria Götze, Avinash Arvind Rasalkar, Vegi M. Naidu et autres

tumor suppressor in Cdx2-driven acute myeloid leukemia

de (code pays fourni par la source)

Gold Nanoparticles with Selective Antileukemic Activity In Vitro and In Vivo Target Mitochondrial Respiration

Ann‐Kathrin Gaiser, Susanne Häfner, Michael Schmiech, Berthold Büchele et autres

Abstract This study explores biocompatible amino‐functionalized gold nanoparticles (Au‐NH2) as nanotherapeutics for the selective eradication of leukemia cells, elucidates the mechanism of cytotoxicity, and it confirms in vivo efficacy of the engineered nanomaterial. Au‐NH2 trigger apoptotic cell death of myeloid leukemia cell …

de, us (code pays fourni par la source)